UNSPSC 51151532: Aceclidine

This classification denotes a cholinergic agonist with the molecular formula C9H15NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0578K3ELIO, chemically known as 3-quinuclidinol, acetate (ester) but generally known as aceclidine, which bears US NIH Compound Identifier 1979. Aceclidine most often comes in forms base, hydrochloride, and salicylate. European Medicines Agency schedules Aceclidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05199MIG.

UNSPSC 51151532 Aceclidine is a Commodity code with minimal recent state and local procurement activity directly aligned to its narrow pharmaceutical scope. The two recent opportunities tagged to this code show a significant mismatch: Seminole County, Florida's IFB60459723LAS solicits naloxone and drug deactivation systems for community health support, and the Texas Health and Human Services Commission's RFI HHS0017013 explores direct-to-manufacturer prescription fulfillment models—neither purchase is aceclidine, a cholinergic agent used in ophthalmology and neurology. The code appears to capture state and local buys of specialized pharmaceuticals through health departments and human services agencies, but recent solicitation activity under this specific code number does not reflect pharmaceutical procurements as typically categorized in state and local taxonomy. No established repeat buyers or procurement pattern emerges from the limited recent opportunities.

Geographic activity involving this code is scattered and sparse. Seminole County's naloxone procurement (response due Jul 26, 2023) and Texas HHS's prescription-program RFI (response deadline Apr 3, 2026) represent the only recent state and local opportunities identified. Neither opportunity directly addresses aceclidine or demonstrates a sustained procurement cycle for drugs at this UNSPSC classification level. The code shows little relevant recent activity and warrants close review before pursuit; business development teams should verify whether aceclidine products are actually being solicited under alternative codes or within broader pharmaceutical-supply RFPs rather than as standalone commodity buys.